{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["13"],"submitter":["Anil TM"],"pubmed_abstract":["Objectives
AMP activated protein kinase (AMPK) regulates the coordination of anabolic and catabolic processes and is an attractive therapeutic target for T2DM, obesity and metabolic syndrome. We report the anti-hyperglycemic and anti-hyperlipidemic effects of CNX-012-570 is an orally bioavailable small molecule (molecular weight of 530 Daltons) that directly activates AMPK in DIO and db/db animal models of diabetes.Methods
Activity and efficacy of the compound was tested in cell based as well as cell free systems in vitro. Male C57BL/6 mice fed with high fat diet (HFD) were assigned to either vehicle or CNX-012-570 (3 mg/kg, orally once a day) for 8 weeks (n = 8). Genetically diabetic db/db mice on chow diet were dosed with vehicle control or CNX-012-570 (2.5 mg/kg, orally "],"journal":["Cardiovascular diabetology"],"pagination":["27"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC3906767"],"repository":["biostudies-literature"],"pubmed_title":["CNX-012-570, a direct AMPK activator provides strong glycemic and lipid control along with significant reduction in body weight; studies from both diet-induced obese mice and db/db mice models."],"pmcid":["PMC3906767"],"pubmed_authors":["Harsha K","Jagannath MR","Balamurali GV","Venkataranganna MV","Govind MK","Moolemath Y","Geetha V","Anil TM","Onkaramurthy M","Somesh BP","Lakshmi MN","Anup MO","Shree N","Sathish Kumar V","Madhusudhan Reddy B","Harish C","Gopala AS"],"additional_accession":[]},"is_claimable":false,"name":"CNX-012-570, a direct AMPK activator provides strong glycemic and lipid control along with significant reduction in body weight; studies from both diet-induced obese mice and db/db mice models.","description":"Objectives
AMP activated protein kinase (AMPK) regulates the coordination of anabolic and catabolic processes and is an attractive therapeutic target for T2DM, obesity and metabolic syndrome. We report the anti-hyperglycemic and anti-hyperlipidemic effects of CNX-012-570 is an orally bioavailable small molecule (molecular weight of 530 Daltons) that directly activates AMPK in DIO and db/db animal models of diabetes.Methods
Activity and efficacy of the compound was tested in cell based as well as cell free systems in vitro. Male C57BL/6 mice fed with high fat diet (HFD) were assigned to either vehicle or CNX-012-570 (3 mg/kg, orally once a day) for 8 weeks (n = 8). Genetically diabetic db/db mice on chow diet were dosed with vehicle control or CNX-012-570 (2.5 mg/kg, orally ","dates":{"release":"2014-01-01T00:00:00Z","publication":"2014 Jan","modification":"2025-04-04T22:47:15.788Z","creation":"2019-03-27T01:20:53Z"},"accession":"S-EPMC3906767","cross_references":{"pubmed":["24460834"],"doi":["10.1186/1475-2840-13-27"]}}